<?xml version="1.0" encoding="UTF-8"?>
  	<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:video="http://www.google.com/schemas/sitemap-video/1.1"><url>
        <loc>https://www.ajmc.com/view/mfps-reshape-payer-negotiations-manufacturer-strategies</loc><video:video><video:publication_date>2026-11-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e97420542688fc91aae4b1f0a90d0b0ce0c3d613-1200x640.png</video:thumbnail_loc><video:title><![CDATA[MFPs Reshape Payer Negotiations, Manufacturer Strategies]]></video:title><video:description><![CDATA[Experts at AMCP Nexus 2026 said payers are using maximum fair prices (MFPs) as leverage while manufacturers rethink rebate and evidence strategies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408292471112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/inebilizumab-benefit-in-gmg-holds-at-1-year-richard-j-nowak-md-ms</loc><video:video><video:publication_date>2026-11-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/b9cdd407c165ed4af2d3a2188b31af5989e3b96d-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Inebilizumab Benefit in gMG Holds at 1 Year: Richard J. Nowak, MD, MS]]></video:title><video:description><![CDATA[One-year open-label MINT data show sustained MG-ADL and QMG score gains with inebilizumab, including in patients who switched from placebo.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408289252112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/transparency-fraud-and-midterms-shape-federal-health-policy-outlook</loc><video:video><video:publication_date>2026-11-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a73c5d8e791e0d1d29b8d61973e779d5439a9e6a-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Transparency, Fraud, and Midterms Shape Federal Health Policy Outlook]]></video:title><video:description><![CDATA[In part 2, Adam Colborn, JD, discussed federal health policy priorities, CMS fraud oversight, and how the midterm elections could shape legislation.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408288643112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/asundexian-shows-broad-stroke-prevention-benefits-safety-mike-sharma-md</loc><video:video><video:publication_date>2026-11-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/97a6a97d52ed3ddd5f78abcb4c5f34633b092728-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Asundexian Shows Broad Stroke Prevention Benefits, Safety: Mike Sharma, MD]]></video:title><video:description><![CDATA[Mike Sharma, MD, discusses the asundexian trial’s broad patient population, results across stroke subtypes, and bleeding outcomes.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408288375112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/all-oral-aml-regimen-phase-2-data-and-inpatient-care-challenges</loc><video:video><video:publication_date>2026-11-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cb444a75a685e0e74bc498a2b9e811c782f2ab01-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[All-Oral AML Regimen: Phase 2 Data and Inpatient Care Challenges]]></video:title><video:description><![CDATA[Phase 2 data show the all-oral regimen performs comparably to intravenous combinations, while inpatient admissions expose gaps in formularies, medication custody, and reimbursement for oral chemotherapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406361823112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/positioning-all-oral-hypomethylating-agent-plus-venetoclax-therapy-in-aml</loc><video:video><video:publication_date>2026-11-12</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cb444a75a685e0e74bc498a2b9e811c782f2ab01-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Positioning All-Oral Hypomethylating Agent Plus Venetoclax Therapy in AML]]></video:title><video:description><![CDATA[An all-oral regimen is a meaningful advance in newly diagnosed AML, yet early monitoring needs, complex dosing, and patient readiness lead many clinicians to begin cycle 1 intravenously.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406364767112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/what-clinicians-want-to-see-next-from-recombinant-aatd-therapy</loc><video:video><video:publication_date>2026-11-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[What Clinicians Want to See Next From Recombinant AATD Therapy]]></video:title><video:description><![CDATA[Equivalent efficacy with fewer infusions would already improve patients' lives, while a superior effect on lung loss or exacerbations would change the treatment threshold. The panel outlines what data would support either outcome.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405745505112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/nccn-guidelines-on-frontline-immunotherapy-in-extensive-stage-sclc</loc><video:video><video:publication_date>2026-11-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f520f6c3b333c5b72da9f5fbfe7eb13e72d2a594-3456x1942.png</video:thumbnail_loc><video:title><![CDATA[NCCN Guidelines on Frontline Immunotherapy in Extensive-Stage SCLC]]></video:title><video:description><![CDATA[As evolving guidelines fold new regimens into category-one recommendations, keeping pace with which combinations qualify as frontline standard has become its own clinical and administrative challenge.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406924498112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/brain-metastases-and-cranial-radiation-in-extensive-stage-sclc</loc><video:video><video:publication_date>2026-11-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f520f6c3b333c5b72da9f5fbfe7eb13e72d2a594-3456x1942.png</video:thumbnail_loc><video:title><![CDATA[Brain Metastases and Cranial Radiation in Extensive-Stage SCLC]]></video:title><video:description><![CDATA[New data challenges a long-standing radiation practice: prophylactic cranial irradiation showed no survival benefit and worse cognitive outcomes, pushing the field toward closer monitoring instead of routine preventive treatment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406923328112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/phase-2-trial-results-for-recombinant-aat-fc-therapy-in-aatd</loc><video:video><video:publication_date>2026-11-11</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[Phase 2 Trial Results for Recombinant AAT-Fc Therapy in AATD]]></video:title><video:description><![CDATA[Phase 2 data show recombinant AAT-Fc therapy restoring normal functional levels with far fewer infusions than plasma-derived augmentation. Whether those levels translate to clinical benefit will depend on longer studies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405745109112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/measles-antibody-testing-on-b3-and-d8-michael-mina-md-phd</loc><video:video><video:publication_date>2026-11-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/408acf5774c29b9f09502c1f5b38ec709aa30120-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Measles Antibody Testing on B3 and D8: Michael Mina, MD, PhD]]></video:title><video:description><![CDATA[Michael Mina, MD, PhD, discusses testing VMS063 against measles B3 and D8 genotypes and how it could fit alongside vaccination.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407978705112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/survodutide-cvot-tests-cv-safety-of-dual-agonist-biykem-bozkurt-md-phd</loc><video:video><video:publication_date>2026-11-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d83edff2646b09080a987f61bd06cd74afa8a8f0-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Survodutide CVOT Tests CV Safety of Dual Agonist: Biykem Bozkurt, MD, PhD]]></video:title><video:description><![CDATA[Biykem Bozkurt, MD, PhD, explains why survodutide, a glucagon and GLP-1 dual agonist, needed a cardiovascular safety trial in patients with obesity.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408150521112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/setting-realistic-treatment-goals-for-vitiligo-patients</loc><video:video><video:publication_date>2026-11-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e96bc9fd5c80c05c78826b3a7421762fb07ce400-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Setting Realistic Treatment Goals for Vitiligo Patients]]></video:title><video:description><![CDATA[Curing vitiligo isn't currently possible, and Dr. Desai says saying so plainly builds trust. He explains how he sets realistic, patient-specific goals around activity control and repigmentation.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406038018112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/choosing-an-il-5-inhibitor-for-asthma-evidence-comorbidities-convenience</loc><video:video><video:publication_date>2026-11-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fdf24b246fbf57d43377a81263eaa9a672fab6d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Choosing an IL-5 Inhibitor for Asthma: Evidence, Comorbidities, Convenience]]></video:title><video:description><![CDATA[Selecting an IL-5 inhibitor begins with evidence and comorbidities, yet dosing schedule and site of care often determine whether patients can remain on therapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406427126112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/positioning-third-line-tkis-in-mcrc</loc><video:video><video:publication_date>2026-11-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ac69bcd3f6a6ac4d3941ef5d2b6a36b933b1684f-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Positioning Third-Line TKIs in mCRC]]></video:title><video:description><![CDATA[Positioning fruquintinib and regorafenib against each other, and against trifluridine and tipiracil plus bevacizumab, increasingly comes down to individual tolerability, disease burden, and appropriate dose escalation strategy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405931680112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/payer-coverage-and-authorization-for-severe-asthma-biologics</loc><video:video><video:publication_date>2026-11-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fdf24b246fbf57d43377a81263eaa9a672fab6d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Payer Coverage and Authorization for Severe Asthma Biologics]]></video:title><video:description><![CDATA[Payer acceptance of asthma biologics has improved considerably, yet coverage still varies widely by health system, and plans can override a treatment choice reached through shared decision-making.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406426132112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/long-term-topical-steroid-use-in-vitiligo-safety-concerns</loc><video:video><video:publication_date>2026-11-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e96bc9fd5c80c05c78826b3a7421762fb07ce400-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Long-Term Topical Steroid Use in Vitiligo: Safety Concerns]]></video:title><video:description><![CDATA[Ultra-potent topical steroids remain effective for vitiligo, but not without cost. Dr. Hamzavi weighs atrophy, systemic hormonal effects, and paradoxical hypopigmentation against the benefits of faster repigmentation.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406040564112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/third-line-treatment-and-optimal-dosing-in-mcrc</loc><video:video><video:publication_date>2026-11-10</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ac69bcd3f6a6ac4d3941ef5d2b6a36b933b1684f-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Third-Line Treatment and Optimal Dosing in mCRC]]></video:title><video:description><![CDATA[The SUNLIGHT trial redefined third-line expectations by pairing trifluridine and tipiracil with bevacizumab, while emerging every-other-week dosing data promise better tolerability without sacrificing efficacy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405931013112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/why-one-exacerbation-matters-in-copd-david-halpin-ma-dphil</loc><video:video><video:publication_date>2026-11-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4ce709230f9a07f353c923d711e847f887ada364-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Why One Exacerbation Matters in COPD: David Halpin, MA, DPhil]]></video:title><video:description><![CDATA[The University of Exeter’s David Halpin, MA, DPhil, explains why GOLD 2026 treats a single COPD exacerbation as a trigger to optimize care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408031634112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/who-needs-a-measles-antibody-most-michael-mina-md-phd</loc><video:video><video:publication_date>2026-11-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/408acf5774c29b9f09502c1f5b38ec709aa30120-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Who Needs a Measles Antibody Most? Michael Mina, MD, PhD]]></video:title><video:description><![CDATA[Michael Mina, MD, PhD, on why babies, immunocompromised patients, and the unvaccinated have the greatest need for a measles antibody.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407979187112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/community-bispecific-delivery-requires-operational-readiness-safety</loc><video:video><video:publication_date>2026-11-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/95bba8368b76fbbf9b5303409a34e29684b694e5-1200x627.png</video:thumbnail_loc><video:title><![CDATA[Community Bispecific Delivery Requires Operational Readiness, Safety]]></video:title><video:description><![CDATA[Establishing baseline oxygen and cognitive assessments helps community teams safely treat older, higher-risk patients, says Salman Fazal, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408140551112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/diabetes-not-bmi-drives-mash-graft-failure-sri-harsha-boppana-md</loc><video:video><video:publication_date>2026-11-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/41139a3e868db11a58d7005908912e8df7564a02-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Diabetes, Not BMI, Drives MASH Graft Failure: Sri Harsha Boppana, MD]]></video:title><video:description><![CDATA[Diabetes and functional dependence predicted 3-year graft loss after MASH liver transplant, while machine learning showed limited predictive power.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408110444112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/early-metabolic-clues-could-detect-masld-sooner-snehal-n-chaudhari-phd</loc><video:video><video:publication_date>2026-11-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/dd4c5b2ab3ea911dd03890bdab9aa56907d1df11-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Early Metabolic Clues Could Detect MASLD Sooner: Snehal N. Chaudhari, PhD]]></video:title><video:description><![CDATA[Gut-derived bile acids disrupt liver metabolism through LRH-1 before visible damage, pointing to new early biomarkers for fatty liver disease.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408123685112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/improving-hs-care-early-detection-awareness-and-reasons-for-optimism</loc><video:video><video:publication_date>2026-11-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/9fb3aeac61b2d2654a816e2ed450a19ba7fa08b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Improving HS Care: Early Detection, Awareness, and Reasons for Optimism]]></video:title><video:description><![CDATA[Earlier recognition requires better tools and wider awareness across medicine and the public. Dr. Lev-Tov sees growing investment, research funding, and a loaded drug pipeline as reasons to be optimistic.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406544783112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/hs-is-not-a-cosmetic-condition-inflammation-symptoms-and-coverage</loc><video:video><video:publication_date>2026-11-09</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/9fb3aeac61b2d2654a816e2ed450a19ba7fa08b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[HS Is Not a Cosmetic Condition: Inflammation, Symptoms, and Coverage]]></video:title><video:description><![CDATA[Calling HS cosmetic is inaccurate and affects coverage decisions. Dr. Lev-Tov lays out the inflammatory, symptomatic, systemic, and functional evidence that this is a serious medical disease.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406542906112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/mash-risk-extends-beyond-bmi-j-rn-m-schattenberg-md</loc><video:video><video:publication_date>2026-11-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/27b2d3bc9f767329715a103f406532c7f25728bc-1200x640.png</video:thumbnail_loc><video:title><![CDATA[MASH Risk Extends Beyond BMI: Jörn M. Schattenberg, MD]]></video:title><video:description><![CDATA[In nonobese patients in the ESSENCE trial, semaglutide improved metabolic dysfunction even with modest weight loss of 2% to 5%.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408110498112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/oral-iberdomide-may-widen-myeloma-access-mateo-mejia-saldarriaga-md</loc><video:video><video:publication_date>2026-11-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c0b0311f60dc3687912ecbefca718ba21cf3ad21-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Oral Iberdomide May Widen Myeloma Access: Mateo Mejia Saldarriaga, MD]]></video:title><video:description><![CDATA[Weill Cornell's Mateo Mejia Saldarriaga, MD, explains why oral options like iberdomide and clinical trials matter in the immunotherapy era of myeloma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406129456112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/precision-myeloma-treatment-close-but-not-yet-nikhil-c-munshi-md</loc><video:video><video:publication_date>2026-11-08</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/8514896eff011790eba6b990f5b70885a63cac32-1200x627.png</video:thumbnail_loc><video:title><![CDATA[Precision Myeloma Treatment Close, but Not Yet: Nikhil C. Munshi, MD]]></video:title><video:description><![CDATA[Myeloma risk prediction is strong, but matching each patient to optimal therapy is still being tested, says Nikhil C. Munshi, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407963505112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/experts-say-early-copd-detection-is-key-to-better-outcomes</loc><video:video><video:publication_date>2026-11-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e59eb5fa6d7bceffdcce7640946154b56b0e1e3f-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Experts Say Early COPD Detection Is Key to Better Outcomes]]></video:title><video:description><![CDATA[Àlvar Agustí, MD PhD; Jadwiga A. Wedzicha, MD; and 3 other experts say earlier diagnosis and intervention could most improve COPD outcomes within 5 years.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408036044112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/glp-1s-lower-mash-activity-but-not-fibrosis-winston-dunn-md-faasld</loc><video:video><video:publication_date>2026-11-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0a063e6d8e72d554e5a3dac137f6fd456cba9484-1200x640.png</video:thumbnail_loc><video:title><![CDATA[GLP-1s Lower MASH Activity but Not Fibrosis: Winston Dunn, MD, FAASLD]]></video:title><video:description><![CDATA[SMART-MASH found about a third more patients with cirrhosis than Agile 4 while using costly fibrosis tests in only some patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408050499112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/pegozafermin-shows-cirrhosis-regression-in-mice-zaur-abilov-md</loc><video:video><video:publication_date>2026-11-07</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/a8880764277a43d7de8682485fe920954c04303b-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Pegozafermin Shows Cirrhosis Regression in Mice: Zaur Abilov, MD]]></video:title><video:description><![CDATA[Started at advanced fibrosis or cirrhosis, pegozafermin lowered liver collagen below baseline and prevented liver cancer in a MASH mouse model.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408053232112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/silent-mucus-plugs-in-copd-emily-s-wan-md</loc><video:video><video:publication_date>2026-11-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2e0ec96f9a42281aad6b385f8cf5f32cf361b2c2-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Silent Mucus Plugs in COPD: Emily S. Wan, MD]]></video:title><video:description><![CDATA[Harvard Medical School’s Emily S. Wan, MD, discusses mucus plugs in COPD, how to detect them, and what would make them a treatment target.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408030443112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/choosing-inhaler-devices-in-copd-david-halpin-ma-dphil</loc><video:video><video:publication_date>2026-11-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4ce709230f9a07f353c923d711e847f887ada364-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Choosing Inhaler Devices in COPD: David Halpin, MA, DPhil]]></video:title><video:description><![CDATA[The University of Exeter’s David Halpin, MA, DPhil, discusses inhaler device selection, single vs multiple inhalers, and the pharmacist’s role in COPD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408032303112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/anti-il-33-biologics-in-copd-francesca-polverino-md-phd</loc><video:video><video:publication_date>2026-11-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/8c354177bd5651c350f77b8bf20c77e79ccc9511-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Anti–IL-33 Biologics in COPD: Francesca Polverino, MD, PhD]]></video:title><video:description><![CDATA[Baylor College of Medicine’s Francesca Polverino, MD, PhD, discusses interleukin-33 and mucus plugging.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408020177112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/medicaid-cuts-and-caregiving-in-congress-andy-kim</loc><video:video><video:publication_date>2026-11-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e6d84de1f5277a3d1cb616644826b93e88e46971-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Medicaid Cuts and Caregiving in Congress: Andy Kim]]></video:title><video:description><![CDATA[Senator Andy Kim (D, New Jersey) discusses plans to reverse Medicaid cuts and make caregiving a priority in the next Congress.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6408024503112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/ms-phenotypes-icd-10-codes-and-payer-barriers-to-treatment</loc><video:video><video:publication_date>2026-11-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/02878616786df975b0ce65508e385490eea62ae5-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[MS Phenotypes, ICD-10 Codes, and Payer Barriers to Treatment]]></video:title><video:description><![CDATA[Treating MS as a continuum conflicts with phenotype-based coding and payer criteria. The panel describes how those frameworks restrict access for patients who are progressing without recent relapses.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407549145112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rezilient3-first-line-zipalertinib-plus-chemotherapy-in-egfr-exon-20-nsclc</loc><video:video><video:publication_date>2026-11-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f51f6463d7e40086370b1eb7c9245cc2fe9f972c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[REZILIENT3: First-Line Zipalertinib Plus Chemotherapy in EGFR Exon 20 NSCLC]]></video:title><video:description><![CDATA[A phase 3 trial of an exon 20-specific oral inhibitor combined with chemotherapy reports improved progression-free survival and response, alongside cytopenias concentrated in the induction phase.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407555166112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/diagnosing-bronchiectasis-why-it-s-often-mistaken-for-asthma-or-copd</loc><video:video><video:publication_date>2026-11-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/7c2be4765575e850218a6d565ecab9816734a293-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Diagnosing Bronchiectasis: Why It's Often Mistaken for Asthma or COPD]]></video:title><video:description><![CDATA[Years of misdiagnosis as asthma or COPD can leave bronchiectasis patients with irreversible lung damage, underscoring the clinical clues physicians need to catch the disease sooner.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405917367112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/measuring-ms-progression-biomarkers-comorbidities-and-rehabilitation</loc><video:video><video:publication_date>2026-11-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/02878616786df975b0ce65508e385490eea62ae5-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Measuring MS Progression: Biomarkers, Comorbidities, and Rehabilitation]]></video:title><video:description><![CDATA[Relapsing and progressive biology coexist in every patient, and clinical tools remain blunt. The panel considers biomarkers, treatable comorbidities, and rehabilitation before attributing worsening to MS progression.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407551012112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/one-bronchiectasis-many-causes-rethinking-disease-classification</loc><video:video><video:publication_date>2026-11-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/7c2be4765575e850218a6d565ecab9816734a293-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[One Bronchiectasis, Many Causes: Rethinking Disease Classification]]></video:title><video:description><![CDATA[Bronchiectasis may have countless underlying causes, but its structural and inflammatory endpoint looks strikingly consistent, a distinction reshaping how the field approaches diagnosis and treatment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405917366112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/unmet-needs-in-egfr-exon-20-nsclc-and-next-generation-oral-tkis</loc><video:video><video:publication_date>2026-11-06</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f51f6463d7e40086370b1eb7c9245cc2fe9f972c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Unmet Needs in EGFR Exon 20 NSCLC and Next-Generation Oral TKIs]]></video:title><video:description><![CDATA[Clinic-based administration, toxicity management, and frequent CNS involvement all add to the burden of this disease, sharpening interest in oral inhibitors built specifically for exon 20 insertions.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407555068112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/anti-alarmin-therapy-in-copd-exacerbations-jadwiga-a-wedzicha-md</loc><video:video><video:publication_date>2026-11-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/9a0e1f8ef26eb1eb78ff4ea858c4a2b2b88fb242-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Anti-Alarmin Therapy in COPD Exacerbations: Jadwiga A. Wedzicha, MD]]></video:title><video:description><![CDATA[Imperial College London’s Jadwiga A. Wedzicha, MD, discusses anti-alarmin trial results in COPD and where biologics may fit in treatment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407971446112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/2027-gold-copd-report-updates-lvar-agust-</loc><video:video><video:publication_date>2026-11-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/784c18108251969fb0165518cb7aa1beccced34c-1200x640.png</video:thumbnail_loc><video:title><![CDATA[2027 GOLD COPD Report Updates: Àlvar Agustí, MD, PhD]]></video:title><video:description><![CDATA[Àlvar Agustí, MD, PhD, discusses what is new in the 2027 GOLD report and why the traditional narrative of COPD needs to change.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407966712112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/national-risk-pool-would-spread-cell-gene-therapy-costs-across-payers</loc><video:video><video:publication_date>2026-11-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/05c69d99b82cc38d52410c5307f4bc0c9ee2dca4-1200x640.png</video:thumbnail_loc><video:title><![CDATA[National Risk Pool Would Spread Cell, Gene Therapy Costs Across Payers]]></video:title><video:description><![CDATA[In an interview at AMCP Nexus 2026, Carmen Witsken, PharmD, of ACHP, outlined a proposed national risk pool for the costliest cell and gene therapies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407919235112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/aml-targeted-therapies-molecular-testing-and-limitations-of-current-regimens</loc><video:video><video:publication_date>2026-11-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cb444a75a685e0e74bc498a2b9e811c782f2ab01-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[AML Targeted Therapies, Molecular Testing, and Limitations of Current Regimens]]></video:title><video:description><![CDATA[Every patient with AML needs comprehensive mutation testing at diagnosis and again at progression, yet even effective targeted and venetoclax-based regimens remain noncurative and carry cumulative toxicity.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406363196112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/venetoclax-combinations-in-aml-viale-a-viale-c-and-practical-challenges</loc><video:video><video:publication_date>2026-11-05</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cb444a75a685e0e74bc498a2b9e811c782f2ab01-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Venetoclax Combinations in AML: VIALE-A, VIALE-C, and Practical Challenges]]></video:title><video:description><![CDATA[Venetoclax combinations have become the backbone of AML therapy for older and unfit patients, but drug interactions, dose modifications, and prior hypomethylating agent exposure complicate real-world use.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406363696112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rare-disease-coverage-decisions-require-ongoing-evidence-review</loc><video:video><video:publication_date>2026-11-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/043f767538132cf7f974af4b01890a38c9a24e72-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Rare Disease Coverage Decisions Require Ongoing Evidence Review]]></video:title><video:description><![CDATA[In part 2, Susan M. Wescott, RPh, MBA, discusses how payers navigate evidence gaps, prior authorization, and access to rare disease therapies.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407862848112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/strengthening-patient-experience-data-reliability-in-payer-decisions</loc><video:video><video:publication_date>2026-11-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/3e3955418581f562d7a1cbabefb21be1440ebadc-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Strengthening Patient Experience Data Reliability in Payer Decisions]]></video:title><video:description><![CDATA[In part 2 of her AMCP Nexus 2026 interview, Jennifer S. Graff, PharmD, discusses improving patient experience data (PED) standardization and credibility.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407862791112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/policy-ai-and-high-cost-therapies-shape-amcp-nexus-2026-discussions</loc><video:video><video:publication_date>2026-11-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/9a7beddc20512618e92a2e5466e569d14b17344e-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Policy, AI, and High-Cost Therapies Shape AMCP Nexus 2026 Discussions]]></video:title><video:description><![CDATA[At AMCP Nexus 2026, experts discussed how drug pricing policy, AI, and high-cost cell and gene therapies may shape managed care in 2027.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407910416112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/how-caspian-and-impower133-inform-treatment-decisions-in-extensive-stage-sclc</loc><video:video><video:publication_date>2026-11-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f520f6c3b333c5b72da9f5fbfe7eb13e72d2a594-3456x1942.png</video:thumbnail_loc><video:title><![CDATA[How CASPIAN and IMpower133 Inform Treatment Decisions in Extensive-Stage SCLC]]></video:title><video:description><![CDATA[With comparable survival benefits and overlapping trial populations, choosing between two frontline immunotherapy regimens increasingly comes down to chemotherapy backbone flexibility and one drug's added indication across both disease stages.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406922556112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/recombinant-aat-fc-fusion-protein-for-aatd-mechanism-and-half-life</loc><video:video><video:publication_date>2026-11-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[Recombinant AAT-Fc Fusion Protein for AATD: Mechanism and Half-Life]]></video:title><video:description><![CDATA[An engineered Fc fusion protein is designed to circulate longer, resist oxidation, and hold levels within the true normal range between infusions, without depending on human plasma.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405746669112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/evidence-for-aatd-augmentation-fev1-limits-ct-density-unmet-needs</loc><video:video><video:publication_date>2026-11-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[Evidence for AATD Augmentation: FEV1 Limits, CT Density, Unmet Needs]]></video:title><video:description><![CDATA[No trial has shown a significant FEV1 benefit, yet FEV1 may be the wrong yardstick for emphysema. CT densitometry and real-world comparisons support augmentation, while testing and liver coordination remain unmet needs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405746097112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/caspian-at-three-years-long-term-survival-in-extensive-stage-sclc</loc><video:video><video:publication_date>2026-11-04</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f520f6c3b333c5b72da9f5fbfe7eb13e72d2a594-3456x1942.png</video:thumbnail_loc><video:title><![CDATA[CASPIAN at Three Years: Long-Term Survival in Extensive-Stage SCLC]]></video:title><video:description><![CDATA[Three-year survival data gives patients something rare in extensive-stage disease: a concrete number to hold onto. Nearly one in five patients alive at three years reframes what a durable tail of the curve can mean.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406924499112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/responsible-ai-adoption-requires-clear-policies-ongoing-oversight</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2184805f817da630554b385f1cedc56fe3a5c8de-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Responsible AI Adoption Requires Clear Policies, Ongoing Oversight]]></video:title><video:description><![CDATA[In part 2, Leanna Baker, PharmD, MS, of Cencora discusses the ongoing costs, governance, and oversight needed for responsible AI adoption.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407860059112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/what-maximum-fair-prices-mean-for-formulary-decision-making</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/063f6d564a7c4c3e49253ada740474c443bf6d22-1200x640.png</video:thumbnail_loc><video:title><![CDATA[What Maximum Fair Prices Mean for Formulary Decision-Making]]></video:title><video:description><![CDATA[Maximum Fair Prices are reshaping Part D formularies, with plans favoring lower net-cost options, panelists said at AMCP Nexus 2026.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407849954112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/cell-gene-therapy-costs-strain-smaller-community-based-health-plans</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/05c69d99b82cc38d52410c5307f4bc0c9ee2dca4-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Cell, Gene Therapy Costs Strain Smaller, Community-Based Health Plans]]></video:title><video:description><![CDATA[At AMCP Nexus 2026, Carmen Witsken, PharmD, discusses high upfront cell and gene therapy costs and the case for a national risk pool.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407802883112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/menopause-therapy-access-limited-by-stigma-coverage-barriers</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/0ccff753cb6a91f8b95fdf0018b03bced7c17ee6-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Menopause Therapy Access Limited by Stigma, Coverage Barriers]]></video:title><video:description><![CDATA[Crescent Moore, PharmD, PhD, discusses provider, coverage, stigma, and education barriers to menopause therapy access.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407805890112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/addressing-patient-hesitancy-toward-biologic-therapy-for-severe-asthma</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fdf24b246fbf57d43377a81263eaa9a672fab6d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Addressing Patient Hesitancy Toward Biologic Therapy for Severe Asthma]]></video:title><video:description><![CDATA[Reluctance toward injectable therapy is diminishing, but it persists. Dosing convenience and an honest conversation about the cumulative harm of steroid bursts can change a patient's decision.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406426810112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/building-an-evidence-matrix-for-sglt2-inhibitor-formulary-decisions</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ae9a6b48cc3fdd455ad435cec5565afde838f6b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Building an Evidence Matrix for SGLT2 Inhibitor Formulary Decisions]]></video:title><video:description><![CDATA[Avoiding the twin traps of treating every SGLT2 inhibitor as identical, or as fundamentally different, Dr. Haumschild lays out an evidence-first framework for the years ahead.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406768290112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/unanswered-questions-in-first-and-second-line-mcrc-care</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ac69bcd3f6a6ac4d3941ef5d2b6a36b933b1684f-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Unanswered Questions in First- and Second-Line mCRC Care]]></video:title><video:description><![CDATA[Unresolved questions about immunotherapy duration, right-sided tumor biology, and earlier use of targeted agents illustrate how much remains unsettled in first- and second-line colorectal cancer management.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405930419112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/first-line-vitiligo-treatment-topical-jak-inhibitors-and-phototherapy</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e96bc9fd5c80c05c78826b3a7421762fb07ce400-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[First-Line Vitiligo Treatment: Topical JAK Inhibitors and Phototherapy]]></video:title><video:description><![CDATA[Topical JAK inhibitors, phototherapy, and combination strategies now anchor first-line vitiligo treatment. Drs. Desai and Hamzavi compare their approaches and the evidence shaping how aggressively they treat localized disease.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406040075112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/mortality-vs-composite-data-comparing-sglt2-inhibitor-trials</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ae9a6b48cc3fdd455ad435cec5565afde838f6b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Mortality vs Composite Data: Comparing SGLT2 Inhibitor Trials]]></video:title><video:description><![CDATA[A shared mechanism and similar composite results can still sit on top of meaningfully different mortality data, and P&T committees need to look past the headline number.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406768183112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/early-biologic-therapy-in-asthma-to-prevent-lung-function-decline</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2fdf24b246fbf57d43377a81263eaa9a672fab6d-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Early Biologic Therapy in Asthma to Prevent Lung Function Decline]]></video:title><video:description><![CDATA[Each exacerbation erodes lung function, and reduced lung function invites the next exacerbation. The panel explains why biologics are shifting from last resort to earlier intervention.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406427305112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/multidisciplinary-care-for-vitiligo-beyond-dermatology</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e96bc9fd5c80c05c78826b3a7421762fb07ce400-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Multidisciplinary Care for Vitiligo: Beyond Dermatology]]></video:title><video:description><![CDATA[Vitiligo care rarely stays within dermatology alone. The panel discusses when to loop in primary care, endocrinology, psychology, and patient support networks to address the disease's full burden.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406038698112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/planning-for-third-line-therapy-and-treatment-rechallenge-in-mcrc</loc><video:video><video:publication_date>2026-11-03</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ac69bcd3f6a6ac4d3941ef5d2b6a36b933b1684f-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Planning for Third-Line Therapy and Treatment Rechallenge in mCRC]]></video:title><video:description><![CDATA[Early planning for third-line therapy, guided by subtle clinical and biochemical signals, now shapes how oncologists distinguish a true treatment rechallenge from a simple reintroduction of prior therapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405931291112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/susceptibility-testing-and-the-future-of-complicated-uti-care</loc><video:video><video:publication_date>2026-11-02</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4eff287dfb8e7017eac085e48cd575aa1a83c830-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Susceptibility Testing and the Future of Complicated UTI Care]]></video:title><video:description><![CDATA[Looking ahead, the panel weighs how a new benchmark therapy will reshape evidence for older agents, where artificial intelligence might fit into individualized prescribing, and why faster, better-validated susceptibility testing remains the field's next hurdle.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405636957112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/hs-comorbidities-navigating-metabolic-bowel-cardiovascular-and-mental-health-risks</loc><video:video><video:publication_date>2026-11-02</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/9fb3aeac61b2d2654a816e2ed450a19ba7fa08b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[HS Comorbidities: Navigating Metabolic, Bowel, Cardiovascular, and Mental Health Risks]]></video:title><video:description><![CDATA[HS is a systemic disease with significant comorbidity, which complicates care. Dr. Lev-Tov argues that published guidelines and clear referral pathways make this burden manageable for dermatologists and other clinicians.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406545264112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/expanding-oral-carbapenem-use-guardrails-and-real-world-evidence-needs</loc><video:video><video:publication_date>2026-11-02</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4eff287dfb8e7017eac085e48cd575aa1a83c830-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Expanding Oral Carbapenem Use: Guardrails and Real-World Evidence Needs]]></video:title><video:description><![CDATA[As oral carbapenem use inevitably extends beyond its approved indication, the panel argues that rigorous, all-oral real-world data, not assumption, should decide how far that use expands and whether hospitalization is truly still necessary.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405636290112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/hs-treatment-window-of-opportunity-moderate-disease-and-early-biologic-therapy</loc><video:video><video:publication_date>2026-11-02</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/9fb3aeac61b2d2654a816e2ed450a19ba7fa08b1-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[HS Treatment Window of Opportunity: Moderate Disease and Early Biologic Therapy]]></video:title><video:description><![CDATA[Earlier treatment appears to improve the likelihood of remission in HS. Dr. Lev-Tov challenges clinicians to rethink what counts as moderate disease and to consider advanced therapies sooner.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406545651112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/permanent-daylight-saving-time-myths-lack-support-karin-johnson-md</loc><video:video><video:publication_date>2026-11-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ec6221d56f88e30fe88e19f9a7ab2a9948901759-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Permanent Daylight Saving Time Myths Lack Support: Karin Johnson, MD]]></video:title><video:description><![CDATA[Karin Johnson, MD, says permanent daylight saving time won’t boost exercise or road safety and that sleep loss from spring clock changes harms health.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407427194112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/myeloma-is-many-diseases-and-treatment-must-reflect-that</loc><video:video><video:publication_date>2026-11-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/8514896eff011790eba6b990f5b70885a63cac32-1200x627.png</video:thumbnail_loc><video:title><![CDATA[Myeloma Is Many Diseases, and Treatment Must Reflect That]]></video:title><video:description><![CDATA[Nikhil C. Munshi, MD, says 25% to 30% of patients with myeloma may now be cured, but relapse and access remain challenges.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407554202112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/rapid-myeloma-advances-demand-ap-education-beth-faiman-phd-msn</loc><video:video><video:publication_date>2026-11-01</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/ff3d923942c7f17659651f0959557fb4af8de296-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Rapid Myeloma Advances Demand AP Education: Beth Faiman, PhD, MSN]]></video:title><video:description><![CDATA[Cleveland Clinic's Beth Faiman, PhD, MSN, says fast-moving myeloma care requires funded education and fewer barriers for advanced practitioner-led care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406374284112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/bronchiectasis-is-underrecognized-obada-shamaa-md-phd</loc><video:video><video:publication_date>2026-10-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/58cd47fcf4b373068c970d9a3b2462d3e9b30f11-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Bronchiectasis Is Underrecognized: Obada Shamaa, MD, PhD]]></video:title><video:description><![CDATA[UChicago Medicine’s Obada Shamaa, MD, PhD, discusses why bronchiectasis is underrecognized and how to personalize airway clearance and antibiotic plans.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407672107112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/ms-progression-explained-relapse-associated-worsening-vs-pira</loc><video:video><video:publication_date>2026-10-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/02878616786df975b0ce65508e385490eea62ae5-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[MS Progression Explained: Relapse-Associated Worsening vs PIRA]]></video:title><video:description><![CDATA[Disability in MS accrues through two distinct biological engines. Recognizing relapse-independent progression changes how clinicians assess patients and how they build trust with those who feel worse despite stable MRI.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407541158112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/selecting-first-line-therapy-in-egfr-exon-20-nsclc-toxicity-and-monitoring</loc><video:video><video:publication_date>2026-10-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f51f6463d7e40086370b1eb7c9245cc2fe9f972c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Selecting First-Line Therapy in EGFR Exon 20 NSCLC: Toxicity and Monitoring]]></video:title><video:description><![CDATA[Efficacy sets the starting point, but performance status, comorbidities, patient priorities, and distinct adverse event patterns determine which first-line regimen a patient actually receives.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407555567112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/how-bronchiectasis-feels-symptoms-and-daily-patient-burden</loc><video:video><video:publication_date>2026-10-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/7c2be4765575e850218a6d565ecab9816734a293-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[How Bronchiectasis Feels: Symptoms and Daily Patient Burden]]></video:title><video:description><![CDATA[Behind every case of bronchiectasis is a self-perpetuating cycle of cough, breathlessness, and infection that leaves many patients unable to return to their prior baseline health.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405917167112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/bronchiectasis-explained-pathophysiology-prevalence-and-evolving-models</loc><video:video><video:publication_date>2026-10-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/7c2be4765575e850218a6d565ecab9816734a293-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Bronchiectasis Explained: Pathophysiology, Prevalence, and Evolving Models]]></video:title><video:description><![CDATA[Bronchiectasis pathophysiology looks less linear and more dynamic than once believed, and its true prevalence appears far higher than commonly assumed across the adult population.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405915886112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/ms-epidemiology-who-is-affected-and-where-unmet-need-remains</loc><video:video><video:publication_date>2026-10-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/02878616786df975b0ce65508e385490eea62ae5-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[MS Epidemiology: Who Is Affected and Where Unmet Need Remains]]></video:title><video:description><![CDATA[MS prevalence continues to rise and the demographic profile is broader than long assumed. The panel identifies progressive biology as the largest remaining unmet need in the disease.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407542041112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/egfr-exon-20-insertion-nsclc-prevalence-testing-and-standard-of-care</loc><video:video><video:publication_date>2026-10-30</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f51f6463d7e40086370b1eb7c9245cc2fe9f972c-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[EGFR Exon 20 Insertion NSCLC: Prevalence, Testing, and Standard of Care]]></video:title><video:description><![CDATA[A rare EGFR subtype demands comprehensive molecular testing at diagnosis, and the first-line standard has shifted from chemotherapy alone to a targeted combination with survival benefit.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407555359112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/precision-medicine-adoption-hindered-by-coverage-education-gaps</loc><video:video><video:publication_date>2026-10-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/db774de823fb870939e9a982cc82c104d3efe487-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Precision Medicine Adoption Hindered by Coverage, Education Gaps]]></video:title><video:description><![CDATA[Pamala A. Pawloski, PharmD, outlines barriers to precision medicine adoption at AMCP Nexus 2026, calling for standardization and education.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407610278112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/closing-the-gap-between-new-ckd-therapies-and-patients-who-need-them</loc><video:video><video:publication_date>2026-10-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/6590d3effd1c18aaeaf2bb4257119cb9a29157be-1200x720.jpg</video:thumbnail_loc><video:title><![CDATA[Closing the Gap Between New CKD Therapies and Patients Who Need Them ]]></video:title><video:description><![CDATA[Experts at ASN Kidney Week say earlier detection, national CKD screening, and faster uptake are needed to bring new therapies to patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407608352112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/right-diagnosis-is-key-to-treating-bipolar-justin-t-ray-pmhnp-bc</loc><video:video><video:publication_date>2026-10-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/b1814dcec7c1e6f84ae7722fd7d6d0ea4fe89433-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Right Diagnosis Is Key to Treating Bipolar: Justin T. Ray, PMHNP-BC]]></video:title><video:description><![CDATA[Bipolar disorder can take 5 to 10 years to diagnose, and missing it can harm patients’ jobs, relationships, finances, and health.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407604855112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/stem-cell-transplant-timing-and-intensive-chemotherapy-trade-offs-in-aml</loc><video:video><video:publication_date>2026-10-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cb444a75a685e0e74bc498a2b9e811c782f2ab01-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Stem Cell Transplant Timing and Intensive Chemotherapy Trade-offs in AML]]></video:title><video:description><![CDATA[Early transplant referral, MRD-guided sequencing, and a candid accounting of intensive chemotherapy's costs shape how clinicians move older and high-risk patients toward potential cure.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406362115112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/newly-diagnosed-aml-treatment-goals-and-current-standard-of-care-regimens</loc><video:video><video:publication_date>2026-10-29</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/cb444a75a685e0e74bc498a2b9e811c782f2ab01-1920x1080.png</video:thumbnail_loc><video:title><![CDATA[Newly Diagnosed AML: Treatment Goals and Current Standard-of-Care Regimens]]></video:title><video:description><![CDATA[From intensive induction with targeted add-ons to lower-intensity venetoclax-based combinations, frontline AML therapy now branches by mutation, fitness, and the realistic prospect of cure without transplant.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406361822112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/health-plans-juggle-the-hope-high-costs-of-rare-disease-drugs</loc><video:video><video:publication_date>2026-10-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/043f767538132cf7f974af4b01890a38c9a24e72-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Health Plans Juggle the Hope, High Costs of Rare Disease Drugs]]></video:title><video:description><![CDATA[At AMCP Nexus 2026, Susan M. Wescott, RPh, MBA, discussed how health plans evaluate rare disease therapies amid limited data and high costs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407552036112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/340b-reform-pbm-policy-among-2027-issues-to-watch-adam-colborn-jd</loc><video:video><video:publication_date>2026-10-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/4b52af5a2cb7787ed47a62f4deb605683c60b9d4-1200x640.png</video:thumbnail_loc><video:title><![CDATA[340B Reform, PBM Policy Among 2027 Issues to Watch: Adam Colborn, JD]]></video:title><video:description><![CDATA[Adam Colborn, JD, discusses 340B reform, PBM policy, site-neutral payment, and other federal health policy issues to watch in 2027.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407514725112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/opportunities-remain-as-us-biosimilar-adoption-advances</loc><video:video><video:publication_date>2026-10-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/e0497503cae7bc9b4236b978b161b454ade38b1f-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Opportunities Remain as US Biosimilar Adoption Advances]]></video:title><video:description><![CDATA[James D. Chambers, PhD, MPharm, MSc, discusses US biosimilar adoption and opportunities to expand patient access and lower treatment costs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407514997112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/patient-experience-data-offer-value-but-pose-evaluation-challenges</loc><video:video><video:publication_date>2026-10-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/3e3955418581f562d7a1cbabefb21be1440ebadc-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Patient Experience Data Offer Value but Pose Evaluation Challenges]]></video:title><video:description><![CDATA[Jennifer S. Graff, PharmD, said payers need clearer standards to assess the reliability and credibility of patient experience data.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407513900112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/health-literacy-drives-trial-access-oyepeju-abioye-akintola-md-msc</loc><video:video><video:publication_date>2026-10-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/83c6279efd397ffd27784defc8ef84bf649f8ef7-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Health Literacy Drives Trial Access: Oyepeju Abioye-Akintola, MD, MSc]]></video:title><video:description><![CDATA[Oyepeju Abioye-Akintola, MD, MSc, says unreadable consent forms are a fixable barrier to oncology trial enrollment.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407537126112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/fast-moving-all-care-outpaces-guidelines-emily-k-curran-md</loc><video:video><video:publication_date>2026-10-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/c5d69fcf5d5618e471613b319e0440fd0f0cee7a-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Fast-Moving ALL Care Outpaces Guidelines: Emily K. Curran, MD ]]></video:title><video:description><![CDATA[Curran urges clinicians to treat ALL treatment guidance as a baseline and, when resources are limited, to focus on what matters most to AYA patients.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407391181112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/aatd-augmentation-adherence-infusion-burden-and-plasma-supply</loc><video:video><video:publication_date>2026-10-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[AATD Augmentation Adherence, Infusion Burden, and Plasma Supply]]></video:title><video:description><![CDATA[Fewer than two-thirds of patients prescribed augmentation begin infusions, and half of starters miss doses. Structured education lifts adherence sharply, while plasma supply and partial coverage expose the limits of current therapy.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405745891112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/caspian-and-impower133-comparing-frontline-trials-in-extensive-stage-sclc</loc><video:video><video:publication_date>2026-10-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f520f6c3b333c5b72da9f5fbfe7eb13e72d2a594-3456x1942.png</video:thumbnail_loc><video:title><![CDATA[CASPIAN and IMpower133: Comparing Frontline Trials in Extensive-Stage SCLC]]></video:title><video:description><![CDATA[Two pivotal trials, built on different designs and chemotherapy backbones, delivered comparable, if modest, survival gains in extensive-stage disease, giving clinicians flexibility while leaving progression-free survival largely unmoved.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406922832112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/extensive-stage-sclc-the-case-for-adding-immunotherapy</loc><video:video><video:publication_date>2026-10-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f520f6c3b333c5b72da9f5fbfe7eb13e72d2a594-3456x1942.png</video:thumbnail_loc><video:title><![CDATA[Extensive-Stage SCLC: The Case for Adding Immunotherapy]]></video:title><video:description><![CDATA[Extensive-stage small cell lung cancer resisted immunotherapy's promise longer than its non-small cell counterpart, but a small, durable subset of long-term survivors justified testing checkpoint inhibitors against a historically difficult tumor.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6406923059112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/weekly-aatd-infusions-peak-to-trough-levels-in-practice</loc><video:video><video:publication_date>2026-10-28</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/585cb91708bcdc69365d3cc6849d7156e53f3f12-770x428.png</video:thumbnail_loc><video:title><![CDATA[Weekly AATD Infusions: Peak-to-Trough Levels in Practice]]></video:title><video:description><![CDATA[Weekly dosing produces high early levels and a falling trough. Panelists explain how they balance exacerbations, travel, and infusion access, and why they discourage routine level monitoring once therapy begins.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6405746376112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/start-small-to-scale-ai-in-managed-care-leanna-baker-pharmd-ms</loc><video:video><video:publication_date>2026-10-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/2184805f817da630554b385f1cedc56fe3a5c8de-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Start Small to Scale AI in Managed Care: Leanna Baker, PharmD, MS]]></video:title><video:description><![CDATA[Managed care organizations should start AI adoption with simple tools that build governance for future growth, Leanna Baker, PharmD, MS, said.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407495065112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/preparing-payers-for-the-next-wave-of-specialty-therapies</loc><video:video><video:publication_date>2026-10-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/d4b79549261e3d92f51e94efc76db290fb1dc673-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Preparing Payers for the Next Wave of Specialty Therapies]]></video:title><video:description><![CDATA[Katelyn B. Meyer, PharmD, discusses how payers can prepare for emerging specialty therapies, from cell and gene therapies to costly oncology drugs.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407491575112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/idweek-2026-recap-care-gaps-and-value-of-collaboration</loc><video:video><video:publication_date>2026-10-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/f92401fdd975ae9e06623d439082592887974174-1200x640.png</video:thumbnail_loc><video:title><![CDATA[IDWeek 2026 Recap: Care Gaps and Value of Collaboration]]></video:title><video:description><![CDATA[At IDWeek 2026, clinicians explained how the meeting breaks down silos and keeps them ahead of what's next in infectious disease care.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407485095112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/povetacicept-cuts-proteinuria-in-igan-richard-lafayette</loc><video:video><video:publication_date>2026-10-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/751dc1455238a6e7d86f0843f6a718bcd4b8e728-1200x640.png</video:thumbnail_loc><video:title><![CDATA[Povetacicept Cuts Proteinuria in IgAN: Richard Lafayette, MD, FACP]]></video:title><video:description><![CDATA[Stanford's Richard Lafayette discusses 36-week povetacicept data in IgA nephropathy, including proteinuria, hematuria, and safety findings.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407484016112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/mrd-could-decide-when-myeloma-maintenance-ends-prerna-mewawalla-md</loc><video:video><video:publication_date>2026-10-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/6133e357a85f6aa2fa1d6dae0837e8f88e02361d-1200x627.png</video:thumbnail_loc><video:title><![CDATA[MRD Could Decide When Myeloma Maintenance Ends: Prerna Mewawalla, MD]]></video:title><video:description><![CDATA[Caution remains necessary when applying ENDURANCE trial findings to high-risk disease, explains Prerna Mewawalla, MD.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407472910112</video:player_loc></video:video></url><url>
        <loc>https://www.ajmc.com/view/payers-health-systems-should-look-beyond-the-icu-chest-2026-recap</loc><video:video><video:publication_date>2026-10-27</video:publication_date><video:thumbnail_loc>https://cdn.sanity.io/images/0vv8moc6/ajmc/06f340f3fca918a33f6db57bb7b00a8d9d987495-1200x720.png</video:thumbnail_loc><video:title><![CDATA[Payers, Health Systems Should Look Beyond the ICU: CHEST 2026 Recap]]></video:title><video:description><![CDATA[Clinicians at CHEST 2026 say costs and outcomes are shaped well beyond the ICU, from surgical choices to discharge planning and end-of-life talks.]]></video:description><video:player_loc allow_embed="yes" autoplay="ap=1">https://players.brightcove.net/10203567001/pbDmfQhRw_default/index.html?videoId=6407433411112</video:player_loc></video:video></url></urlset>